Qing-Yin Wang

Qing-Yin Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Qing-Yin Wang has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Pei-Yong Shi

    Novartis Institute for Tropical Diseases, Singapore

    4 shared publications
  • Hao Ying Xu

    Novartis Institute for Tropical Diseases, Singapore 138670, Singapore,1 State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Science, China2

    2 shared publications
  • Jing Zou

    Novartis Institute for Tropical Diseases, Singapore; State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, China; University of Chinese Academy of Sciences, Beijing, China

    2 shared publications
  • Subhash G. Vasudevan

    Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore

    2 shared publications
  • Xuping Xie

    Novartis Institute for Tropical Diseases, Singapore

    2 shared publications
  • Christian G. Noble

    Novartis Institute for Tropical Diseases, 10 Biopolis Road, 05-01, Chromos, Singapore 138670, Singapore

    1 shared publication

Latest Publications

  • Small Molecule Drug Development for Dengue Virus

    by Qing-Yin Wang, Pei-Yong Shi

    A panel of expert arbovirologists review the most important arbovirus research literature, and identify the most pressing questions that remain to be answered. Topics range from taxonomy and genome organization, to arbovirus diagnostics and control. Essential reading.

  • Targeting dengue virus NS4B protein for drug discovery

    by Xuping Xie, Jing Zou, Qing-Yin Wang, Pei-Yong Shi


  • Generation and characterization of mouse monoclonal antibodies against NS4B protein of dengue virus

    by Xuping Xie, Jing Zou, Qing-Yin Wang, Christian G. Noble, Julien Lescar, Pei-Yong Shi


  • Characterization of Dengue Virus Resistance to Brequinar in Cell Culture

    by Min Qing, Gang Zou, Qing-Yin Wang, Hao Ying Xu, Hongping Dong, Zhiming Yuan, Pei-Yong Shi

    Brequinar is an inhibitor of dihydroorotate dehydrogenase, an enzyme that is required for de novo pyrimidine biosynthesis. Here we report that brequinar has activity against a broad spectrum of viruses. The compound not only inhibits flaviviruses (dengue virus, West Nile virus, yellow fever virus, and Powassan virus) but also suppresses a plus-strand RNA alphavirus (Western equine encephalitis virus) and a negative-strand RNA rhabdovirus (vesicular stomatitis virus). Using dengue virus serotype 2 (DENV-2) as a model, we found that brequinar suppressed the viral infection cycle mainly at the step of RNA synthesis. Supplementing the culture medium with pyrimidines (cytidine or uridine) but not purines (adenine or guanine) could be used to reverse the inhibitory effect of the compound. Continuous culturing of DENV-2 in the presence of brequinar generated viruses that were partially resistant to the inhibitor. Sequencing of the resistant viruses revealed two amino acid mutations: one mutation (M260V) located at a helix in the domain II of the viral envelope protein and another mutation (E802Q) located at the priming loop of the nonstructural protein 5 (NS5) polymerase domain. Functional analysis of the mutations suggests that the NS5 mutation exerts resistance through enhancement of polymerase activity. The envelope protein mutation reduced the efficiency of virion assembly/release; however, the mutant virus became less sensitive to brequinar inhibition at the step of virion assembly/release. Taken together, the results indicate that (i) brequinar blocks DENV RNA synthesis through depletion of intracellular pyrimidine pools and (ii) the compound may also exert its antiviral activity through inhibition of virion assembly/release.


  • A Small-Molecule Dengue Virus Entry Inhibitor

    by Qing-Yin Wang, Sejal J. Patel, Eric Vangrevelinghe, Hao Ying Xu, Ranga Rao, Deana Jaber, Wouter Schul, Feng Gu, Olivier Heudi, Ngai Ling Ma, et al.

    The incidence of dengue fever epidemics has increased dramatically over the last few decades. However, no vaccine or antiviral therapies are available. Therefore, the need for safe and effective antiviral drugs has become imperative. The entry of dengue virus into a host cell is mediated by its major envelope (E) protein. The crystal structure of the E protein reveals a hydrophobic pocket that is presumably important for low-pH-mediated membrane fusion. High-throughput docking with this hydrophobic pocket was performed, and hits were evaluated in cell-based assays. Compound 6 was identified as one of the inhibitors and had an average 50% effective concentration of 119 nM against dengue virus serotype 2 in a human cell line. Mechanism-of-action studies demonstrated that compound 6 acts at an early stage during dengue virus infection. It arrests dengue virus in vesicles that colocalize with endocytosed dextran and inhibits NS3 expression. The inhibitors described in this report can serve as molecular probes for the study of the entry of flavivirus into host cells.


  • Open Access

    Dengue virus serotype infection specifies the activation of the unfolded protein response

    by Indira Umareddy, Olivier Pluquet, Qing Yin Wang, Subhash G Vasudevan, Eric Chevet, Feng Gu

    Background: Dengue and Dengue hemorrhagic fever have emerged as some of the most important mosquito-borne viral diseases in the tropics. The mechanisms of pathogenesis of Dengue remain elusive. Recently, virus-induced apoptosis mediated by the Unfolded Protein Response (UPR) has been hypothesised to represent a crucial pathogenic event in viral infection. In an attempt to evaluate the contribution of the UPR to virus replication, we have characterized each component of this signalling pathway following Dengue virus infection. Results: We find that upon Dengue virus infection, A549 cells elicit an UPR which is observed at the level of translation attenuation (as visualized by the phosphorylation of eIF2alpha) and activation of specific pathways such as nuclear translocation of ATF-6 and splicing of XBP-1. Interestingly, we find that specific serotype of virus modulate the UPR with different selectivity. In addition, we demonstrate that perturbation of the UPR by preventing the dephosphorylation of the translation initiation factor eIF2alpha using Salubrinal considerably alters virus infectivity. Conclusion: This report provides evidence that Dengue infection induces and regulates the three branches of the UPR signaling cascades. This is a basis for our understanding of the viral regulation and conditions beneficial to the viral infection. Furthermore, modulators of UPR such as Salubrinal that inhibit Dengue replication may open up an avenue toward cell-protective agents that target the endoplasmic reticulum for anti-viral therapy.